MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/bmjresp-2023-001864

Медицинская библиотека · BMJ open respiratory research · 2023

Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry.

Tsubouchi Kazuya, Hamada Naoki, Tokunaga Shoji, Ichiki Katsuyuki, Takata Shohei, Ishii Hiroshi, Kitasato Yasuhiko, Okamoto Masaki, Kawakami Satoru, Yatera Kazuhiro, Kawasaki Masayuki, Fujita Masaki, Yoshida Makoto, Maeyama Takashige, Harada Taishi, Wataya Hiroshi, Torii Ryo, Komori Masashi, Mizuta Yuichi, Tobino Kazunori, Harada Eiji, Yabuuchi Hidetake, Nakanishi Yoichi, Okamoto Isamu

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

Few prospective cohort studies with relatively large numbers of patients with non-idiopathic pulmonary fibrosis (non-IPF) of idiopathic interstitial pneumonia (IIP) have been described. We aimed to assess disease progression and cause of death for patients with non-IPF IIPs or IPF under real-life conditions.

METHODS

Data were analysed for a prospective multi-institutional cohort of 528 IIP patients enrolled in Japan between September 2013 and April 2016. Diagnosis of IPF versus non-IPF IIPs was based on central multidisciplinary discussion, and follow-up surveillance was performed for up to 5 years after patient registration. Survival and acute exacerbation (AE) were assessed.

RESULTS

IPF was the most common diagnosis (58.0%), followed by unclassifiable IIPs (35.8%) and others (6.2%). The 5-year survival rate for non-IPF IIP and IPF groups was 72.8% and 53.7%, respectively, with chronic respiratory failure being the primary cause of death in both groups. AE was the second most common cause of death for both non-IPF IIP (24.1%) and IPF (23.5%) patients. The cumulative incidence of AE did not differ significantly between the two groups (p=0.36), with a 1-year incidence rate of 7.4% and 9.0% in non-IPF IIP and IPF patients, respectively. We found that 30.2% and 39.4% of non-IPF IIP and IPF patients, respectively, who experienced AE died within 3 months after an AE event, whereas 55.8% and 66.7% of such patients, respectively, died within 5 years after registration.

CONCLUSION

Closer monitoring of disease progression and palliative care interventions after AE are important for non-IPF IIP patients as well as for IPF patients.

Для цитирования: Tsubouchi Kazuya, Hamada Naoki, Tokunaga Shoji, Ichiki Katsuyuki, Takata Shohei, Ishii Hiroshi, Kitasato Yasuhiko, Okamoto Masaki, Kawakami Satoru, Yatera Kazuhiro, Kawasaki Masayuki, Fujita Masaki, Yoshida Makoto, Maeyama Takashige, Harada Taishi, Wataya Hiroshi, Torii Ryo, Komori Masashi, Mizuta Yuichi, Tobino Kazunori, Harada Eiji, Yabuuchi Hidetake, Nakanishi Yoichi, Okamoto Isamu. Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry.. BMJ open respiratory research. 2023. DOI: 10.1136/bmjresp-2023-001864.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.